Skip to content
HelixEVOLabs home
Sign in
HelixEVO LabsTirzepatide40 mgLOT ________For research use only. Not for human or veterinary use.STORE 2–8 °CHelixEVO LabsTirzepatide40 mgLOT ________For research use only.Not for human or veterinary use.STORE 2–8 °C
Research peptide

Tirzepatide

Tirzepatide

Specification
Total quantity
40 mg
Pack
Sealed glass vial(s); vial count confirmed before release
Form
Lyophilised powder
Stated purity
Reported per lot on the certificate of analysis
Appearance
Lyophilised white to practically white hygroscopic powder in a sealed glass vial.
Storage
2–8 °C, sealed, protected from light
Shipping
Dispatched from the United Kingdom under cold chain, Monday to Wednesday only, so that no consignment is held in transit over a weekend. Insulated packaging with gel coolant, on a tracked service.
SKU
HX-TIRZ-40
AvailabilityOut of stock

Pricing releasing soon. Leave an email to be told once, or request a wholesale quote now.

Request a wholesale quote
For laboratory research use only. Not for human or veterinary consumption.

Analytical data

Latest released lotNo released lot yet

Analytical data appear here as soon as the first lot is released. Every released lot carries a certificate with HPLC purity and MS identity per compound.

Method

Purity by reversed-phase HPLC with UV detection; identity by electrospray mass spectrometry against the calculated monoisotopic or average mass. Endotoxin where stated. The certificate names the laboratory and the method for every result.

How to read a certificate →

Identity

Identity · Tirzepatideverified 2026-09-21
In this product
40 mg
Synonyms
LY3298176, LY-3298176, Mounjaro, Zepbound, Tirzepatide [INN], Tirzepatide [USAN], Tirzepatide [JAN]
CAS
2023788-19-2· National Center for Biotechnology Information, NIH NCATS / FDA Global Substance Registration System
UNII
OYN3CCI6QE· NIH NCATS / FDA Global Substance Registration System, Eli Lilly and Company via DailyMed (US National Library of Medicine)
PubChem CID
166567236
Formula
C225H348N48O68· National Center for Biotechnology Information, European Medicines Agency, Eli Lilly and Company via DailyMed (US National Library of Medicine), NIH NCATS / FDA Global Substance Registration System
Mol. weight
4813.45 g/mol· European Medicines Agency, Eli Lilly and Company via DailyMed (US National Library of Medicine), National Center for Biotechnology Information, NIH NCATS / FDA Global Substance Registration System
Class
Synthetic acylated 39-residue peptide; dual GIP receptor and GLP-1 receptor agonist; ATC code A10BX16
Targets
GIP receptor (agonist), GLP-1 receptor (agonist)
Modifications
2-Aminoisobutyric acid (Aib, non-coded) at positions 2 and 13; C-terminal amide (serinamide at position 39); Lys20 side chain attached to 1,20-eicosanedioic acid (C20 fatty diacid) via a linker of one gamma-Glu and two 8-amino-3,6-dioxaoctanoic acid units; All coded residues in the L configuration; Gly and Aib have no chiral centre; Peptide component based on the GIP sequence; Manufactured by solid-phase peptide synthesis
Sequence (one-letter) · 39 residues
  1. Y
  2. X
  3. E
  4. G
  5. T
  6. F
  7. T
  8. S
  9. D
  10. Y
  11. S
  12. I
  13. X
  14. L
  15. D
  16. K
  17. I
  18. A
  19. Q
  20. K
  21. A
  22. F
  23. V
  24. Q
  25. W
  26. L
  27. I
  28. A
  29. G
  30. G
  31. P
  32. S
  33. S
  34. G
  35. A
  36. P
  37. P
  38. P
  39. S

Research overview

Tirzepatide, developed under the code LY3298176, is a synthetic fatty-acid-modified peptide with dual agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor 1. The FDA substance registry records a 39-residue chain whose two 2-aminoisobutyric acid residues, at positions 2 and 13, are held separately from the subunit string, together with a C-terminal amide at serine 39 2. A plain copy of that one-letter string therefore loses the two non-coded residues, the acylation at lysine 20 and the C-terminal amide 2. The molecular formula is C225H348N48O68 and the CAS number 2023788-19-2, with a monoisotopic mass of 4810.52 Da and an average mass near 4813 for the free peptide 32. Five PubChem records share the name and the CAS number but differ in stereochemistry, and PubChem designates no preferred record; the record used here is the one matching the all-L configuration of the regulatory chemical name 3. The analytical literature follows from the synthesis route. Process chemists at the originator describe diketopiperazine formation and the associated double-amino-acid deletion impurities which arise at the C-terminal proline-proline-serine region during solid-phase synthesis, together with control measures 4. An isocratic RP-HPLC method with diode-array detection reports elution at 1.68 minutes, linearity from 1 to 500 micrograms per mL and a limit of detection of 10 ng/mL 5. This material is supplied for laboratory research only.

  1. 1.Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism (2018). doi:10.1016/j.molmet.2018.09.009
  2. 2.TIRZEPATIDE - Global Substance Registration System record, UNII OYN3CCI6QE. NIH NCATS / FDA Global Substance Registration System (2026). source
  3. 3.Tirzepatide - PubChem Compound CID 166567236 (PUG REST properties and synonyms). National Center for Biotechnology Information (2026). source
  4. 4.Wang J, Berglund MR, Braden T, Embry MC, Johnson MD, Groskreutz SR, Sayyed FB, Tsukanov SV, White TD, Jalan A, Seibert KD, Kopach ME. Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide. ACS Omega (2022). doi:10.1021/acsomega.2c05915
  5. 5.Khalil HA, Hassanein NA, El-Yazbi AF, Mahgoub H. A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal. BMC Chemistry (2026). doi:10.1186/s13065-025-01716-7
Tirzepatide monograph

Regulatory status

Regulatory status · TirzepatideActive substance of a licensed medicine

This material is a research-grade chemical. It is not a medicinal product, has not been manufactured under GMP for medicinal use, and is not the licensed medicine whose active substance shares its name. It is supplied for laboratory research only.

The regulatory rows below describe the authorisation status of medicines containing this substance in each jurisdiction. They say nothing about this material, which is not authorised for any use in or on humans or animals.

United Kingdom
Mounjaro (tirzepatide) is an authorised prescription medicine in Great Britain for type 2 diabetes (adults, adolescents and children aged 10 years and above) and for weight management in adults, and is under additional monitoring.Checked 2026-09-21 · electronic medicines compendium (Datapharm); Eli Lilly and Company Limited
European Union
Mounjaro (tirzepatide, EMEA/H/C/005620, Eli Lilly Nederland B.V.) has been centrally authorised since 15 September 2022 for type 2 diabetes and, following a CHMP opinion of 9 November 2023, for weight management; EMA did not recommend separate indications for obstructive sleep apnoea, HFpEF or cardiovascular risk reduction.Checked 2026-09-21 · European Medicines Agency
United States
FDA-approved as Mounjaro (NDA 215866, 13 May 2022) and Zepbound (NDA 217806, 8 November 2023); FDA determined the tirzepatide injection shortage resolved on 19 December 2024, the compounding enforcement-discretion periods have ended, and FDA states tirzepatide is on neither the 503B bulks list nor the drug shortage list.Checked 2026-09-21 · US Food and Drug Administration
WADA Prohibited List
Tirzepatide is not named on the 2026 WADA Prohibited List as rendered on WADA's website; 'Markers of Semaglutide and Tirzepatide' are on the 2026 Monitoring Program (in and out of competition), which covers substances that are not on the Prohibited List.Checked 2026-09-21 · World Anti-Doping Agency
Handling and safety

Handle as a research chemical of unknown hazard in a laboratory setting with appropriate protective equipment. Keep sealed at 2–8 °C and protected from light. Safety data sheet: available on request until the SDS is published here.

Shipping

Dispatched in insulated cold-chain packaging with a coolant, Monday to Wednesday, to laboratory and business addresses within the United Kingdom. Destination rules are on the shipping policy.

Questions

What identity data are recorded for this material?
The identity used throughout the knowledge base is CAS 2023788-19-2, UNII OYN3CCI6QE and PubChem CID 166567236, with the molecular formula C225H348N48O68 and a monoisotopic mass of 4810.52 Da [pubchem-166567236][gsrs-tirzepatide]. The substance registry carries a different formula, flagged in the registry itself as estimated, and the conflict is recorded in the research dossier rather than resolved [gsrs-tirzepatide].
How is purity established, and against what?
Purity is reported as reversed-phase HPLC main-peak content, with identity confirmed by high-resolution mass spectrometry. A published isocratic RP-HPLC method with diode-array detection reports tirzepatide eluting at 1.68 minutes, linearity from 1 to 500 micrograms per mL and a limit of detection of 10 ng/mL, with separation from degradants formed under acidic, basic, oxidative and photolytic stress [khalil-2026-bmcchem].
What does the certificate of analysis cover?
Each lot is released against its own certificate of analysis, which records the identity and purity results, the methods used and the lot number, so that a vial can be matched to its record. No pharmacopoeial monograph for tirzepatide was retrieved in the research behind this listing, and no named impurity specification is published in an allowed source.
Which process-related impurities does the literature describe?
Process chemists at the originator describe diketopiperazine formation and the associated double-amino-acid deletion impurities which arise at the C-terminal proline-proline-serine region during solid-phase synthesis, along with control measures including Bsmoc protection, oxyma additives and a lower intermediate storage temperature [wang-2022-acsomega].
What storage condition is listed for this material?
The listed storage condition is 2 to 8 °C, and the condition under which a lot was held is recorded on its certificate of analysis. No allowed source retrieved for the research dossier gives stability data for lyophilised or redissolved research-grade material, so no literature shelf-life figure is quoted here.
What does a pack contain?
A pack contains a total of 40 mg of tirzepatide as lyophilised powder in sealed glass vials. Until the split of that total across vials has been confirmed for a lot, the listing states the total quantity only.